McKesson to Acquire Majority Stake in Florida Cancer Specialists & Research Institute’s Core Ventures

McKesson Corporation (NYSE: MCK) has announced a definitive agreement to acquire a controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures) for approximately $2.49 billion in cash, representing about 70% ownership. Core Ventures, created by Florida Cancer Specialists…

Read MoreMcKesson to Acquire Majority Stake in Florida Cancer Specialists & Research Institute’s Core Ventures

Delcath Systems Reveals Positive Results from Independent Study on Repeated Hepatic Chemosaturation

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology firm specializing in liver cancer treatment, has announced the publication of an independent study by researchers at the University Hospital of Leipzig, Germany. Published in the European Society for Medical Oncology’s journal…

Read MoreDelcath Systems Reveals Positive Results from Independent Study on Repeated Hepatic Chemosaturation

KARL STORZ and Fujifilm Forge Strategic Partnership to Revolutionize Endoscopy

KARL STORZ United States, a global leader in Operating Room (OR) integration, has partnered with FUJIFILM Healthcare Americas Corporation to deliver advanced solutions for endoscopists and surgeons. This collaboration combines KARL STORZ’s expertise in OR integration with Fujifilm’s cutting-edge endoscopic…

Read MoreKARL STORZ and Fujifilm Forge Strategic Partnership to Revolutionize Endoscopy

Masimo SET® Pulse Oximetry: Superior Performance, Global Reach, Lasting Impact

Masimo (NASDAQ: MASI) Signal Extraction Technology® (SET®) pulse oximetry, known for its industry-leading accuracy and clinical validation, continues to set the standard in overcoming the limitations of conventional pulse oximetry. As of 2024, Masimo SET® is the primary pulse oximetry…

Read MoreMasimo SET® Pulse Oximetry: Superior Performance, Global Reach, Lasting Impact